{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T23:04:33Z","timestamp":1784761473615,"version":"3.55.0"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T00:00:00Z","timestamp":1755129600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Mycoplasma pneumoniae is a common respiratory pathogen of increasing clinical interest due to a recent rise in cases in the United States and worldwide following a period of reduced activity during the COVID-19 pandemic. While most cases are mild, M pneumoniae can cause severe community-acquired pneumonia (CAP), and cannot be reliably distinguished from other common causes of CAP based solely on features of clinical presentation or imaging. However, testing to confirm a diagnosis of M pneumoniae, when it is suspected, can be logistically challenging in some clinical settings. It also remains unclear which patients with M pneumoniae CAP benefit from antibiotic treatment, which raises the question of whether treatment should be offered, particularly when the diagnosis is not confirmed. This pro\/con discussion explores the available data to support or refute routine testing and empiric antibiotic treatment for M pneumoniae.<\/jats:p>","DOI":"10.1093\/jpids\/piaf075","type":"journal-article","created":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T11:59:55Z","timestamp":1755172795000},"source":"Crossref","is-referenced-by-count":4,"title":["Empiric Antibiotic Therapy for <i>Mycoplasma pneumoniae<\/i> Pneumonia in Children: A Pro\/Con Discussion"],"prefix":"10.1093","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-5677-6145","authenticated-orcid":false,"given":"Elizabeth C","family":"Lloyd","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Division of Pediatric Infectious Diseases, University of Michigan Medical School , Ann Arbor, MI ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9912-3646","authenticated-orcid":false,"given":"Joshua","family":"Wolf","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, St. Jude Children\u2019s Research Hospital and Department of Pediatrics, University of Tennessee Health Science Center , Memphis, TN ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,8,14]]},"reference":[{"key":"2025091815491414900_ref1","doi-asserted-by":"publisher","DOI":"10.1093\/jpids\/piaf006","article-title":"Walking (pneumonia) down memory lane: Mycoplasma pneumoniae returns","volume":"14","author":"Same","year":"2025","journal-title":"J Pediatric Infect Dis Soc"},{"key":"2025091815491414900_ref2","doi-asserted-by":"publisher","first-page":"piae117","DOI":"10.1093\/jpids\/piae117","article-title":"Macrolide-Resistant Mycoplasma pneumoniae, North Dakota 2024","volume":"14","author":"Douvoyiannis","year":"2025","journal-title":"J Pediatric Infect Dis Soc"},{"key":"2025091815491414900_ref3","doi-asserted-by":"crossref","first-page":"piae119","DOI":"10.1093\/jpids\/piae119","article-title":"Resurgence of pediatric Mycoplasma pneumoniae infections in Southeast Texas, November 2023-June 2024","volume":"14","author":"Danner","year":"2025","journal-title":"J Pediatric Infect Dis Soc"},{"key":"2025091815491414900_ref4","doi-asserted-by":"publisher","first-page":"piae132","DOI":"10.1093\/jpids\/piae132","article-title":"Increasing number of clinically severe Mycoplasma pneumoniae infections in children after the COVID-19 pandemic: a single-center case series","volume":"14","author":"McCarthy","year":"2025","journal-title":"J Pediatric Infect Dis Soc"},{"key":"2025091815491414900_ref5","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1056\/NEJMoa1405870","article-title":"Community-acquired pneumonia requiring hospitalization among U.S. children","volume":"372","author":"Jain","year":"2015","journal-title":"N Engl J Med"},{"key":"2025091815491414900_ref6","doi-asserted-by":"publisher","first-page":"394","DOI":"10.15585\/mmwr.mm7423a1","article-title":"Mycoplasma pneumoniae infections in hospitalized children\u2014United States, 2018\u20132024","volume":"74","author":"Diaz","year":"2025","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2025091815491414900_ref7","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1093\/cid\/ciy419","article-title":"Mycoplasma pneumoniae among children hospitalized with community-acquired pneumonia","volume":"68","author":"Kutty","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2025091815491414900_ref8","article-title":"Mycoplasma pneumoniae and Other Mycoplasma Species Infections","volume-title":"Red Book: 2024\u20132027 Report of the Committee on Infectious Diseases"},{"key":"2025091815491414900_ref9","doi-asserted-by":"publisher","first-page":"e25","DOI":"10.1093\/cid\/cir531","article-title":"Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America","volume":"53","author":"Bradley","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2025091815491414900_ref10","first-page":"CD004875","article-title":"Antibiotics for community-acquired lower respiratory tract infections secondary to Mycoplasma pneumoniae in children","volume":"1","author":"Gardiner","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"2025091815491414900_ref11","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1542\/peds.2013-3729","article-title":"Treatment of Mycoplasma pneumonia: a systematic review","volume":"133","author":"Biondi","year":"2014","journal-title":"Pediatrics"},{"key":"2025091815491414900_ref12","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1093\/jpids\/pix083","article-title":"Macrolides in children with community-acquired pneumonia: panacea or placebo?","volume":"7","author":"Blyth","year":"2018","journal-title":"J Pediatric Infect Dis Soc"},{"key":"2025091815491414900_ref13","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009175.pub2","volume":"10","author":"Wang","journal-title":"Cochrane Database Syst Rev"},{"key":"2025091815491414900_ref14","doi-asserted-by":"publisher","first-page":"10002","DOI":"10.7189\/jogh.12.10002","article-title":"A systematic review of the clinical features of pneumonia in children aged 5-9 years: implications for guidelines and research","volume":"12","author":"Kevat","year":"2022","journal-title":"J Glob Health"},{"key":"2025091815491414900_ref15","doi-asserted-by":"publisher","first-page":"113333","DOI":"10.1016\/j.jpeds.2023.01.010","article-title":"Association of radiology findings with etiology of community acquired pneumonia among children","volume":"261","author":"Arnold","year":"2023","journal-title":"J Pediatr"},{"key":"2025091815491414900_ref16","doi-asserted-by":"publisher","first-page":"e0113924","DOI":"10.1128\/jcm.01139-24","article-title":"Reduced sensitivity of a multiplex commercial respiratory panel for detection of Mycoplasma pneumoniae is due to specimen type","volume":"62","author":"Leber","year":"2024","journal-title":"J Clin Microbiol"},{"key":"2025091815491414900_ref17","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.jpeds.2017.06.038","article-title":"Comparison of oropharyngeal and nasopharyngeal swab specimens for the detection of Mycoplasma pneumoniae in children with lower respiratory tract infection","volume":"189","author":"Kakuya","year":"2017","journal-title":"J Pediatr"},{"key":"2025091815491414900_ref18","doi-asserted-by":"publisher","first-page":"e2220949","DOI":"10.1001\/jamanetworkopen.2022.20949","article-title":"Global trends in the proportion of macrolide-resistant Mycoplasma pneumoniae infections: a systematic review and meta-analysis","volume":"5","author":"Kim","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2025091815491414900_ref19","doi-asserted-by":"publisher","first-page":"e0243221","DOI":"10.1128\/aac.02432-21","article-title":"Macrolide resistance in Mycoplasma pneumoniae, Midwestern United States, 2014 to 2021","volume":"66","author":"Rothstein","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2025091815491414900_ref20","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.3201\/eid2310.170106","article-title":"Macrolide-resistant Mycoplasma pneumoniae infection, Japan, 2008-2015","volume":"23","author":"Tanaka","year":"2017","journal-title":"Emerg Infect Dis"},{"key":"2025091815491414900_ref21","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.diagmicrobio.2010.03.004","article-title":"Characterization of macrolide resistance in Mycoplasma pneumoniae isolated from children in Shanghai","volume":"67","author":"Liu","year":"2010","journal-title":"China Diagn Microbiol Infect Dis"},{"key":"2025091815491414900_ref22","doi-asserted-by":"publisher","first-page":"2100746","DOI":"10.2807\/1560-7917.ES.2022.27.19.2100746","article-title":"Mycoplasma pneumoniae detections before and during the COVID-19 pandemic: results of a global survey, 2017 to 2021","volume":"27","author":"Meyer Sauteur","year":"2022","journal-title":"Euro Surveill"},{"key":"2025091815491414900_ref23","doi-asserted-by":"crossref","first-page":"e00968","DOI":"10.1128\/JCM.00968-19","article-title":"Macrolide-resistant Mycoplasma pneumoniae in the United States as determined from a national surveillance program","volume":"57","author":"Waites","year":"2019","journal-title":"J Clin Microbiol"},{"key":"2025091815491414900_ref24","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1128\/JCM.02597-14","article-title":"Investigations of Mycoplasma pneumoniae infections in the United States: trends in molecular typing and macrolide resistance from 2006 to 2013","volume":"53","author":"Diaz","year":"2015","journal-title":"J Clin Microbiol"},{"key":"2025091815491414900_ref25","doi-asserted-by":"crossref","first-page":"e00242","DOI":"10.1128\/JCM.00242-20","article-title":"Evaluation of commercial molecular diagnostic methods for detection and determination of macrolide resistance in Mycoplasma pneumoniae","volume":"58","author":"Leal","year":"2020","journal-title":"J Clin Microbiol"},{"key":"2025091815491414900_ref26","doi-asserted-by":"publisher","first-page":"104868","DOI":"10.1016\/j.ebiom.2023.104868","article-title":"Mycoplasma pneumoniae carriage in children with recurrent respiratory tract infections is associated with a less diverse and altered microbiota","volume":"98","author":"Koenen","year":"2023","journal-title":"EBioMedicine"},{"key":"2025091815491414900_ref27","doi-asserted-by":"publisher","first-page":"e1001444","DOI":"10.1371\/journal.pmed.1001444","article-title":"Carriage of Mycoplasma pneumoniae in the upper respiratory tract of symptomatic and asymptomatic children: an observational study","volume":"10","author":"Spuesens","year":"2013","journal-title":"PLoS Med"},{"key":"2025091815491414900_ref28","doi-asserted-by":"crossref","first-page":"ofae470","DOI":"10.1093\/ofid\/ofae470","article-title":"High rates of nonsusceptibility to common oral antibiotics in Streptococcus pneumoniae clinical isolates from the United States (2019-2021)","volume":"11","author":"Deshpande","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"2025091815491414900_ref29","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1016\/j.jpeds.2012.06.067","article-title":"Comparative effectiveness of empiric \u03b2-lactam monotherapy and \u03b2-lactam-macrolide combination therapy in children hospitalized with community-acquired pneumonia","volume":"161","author":"Ambroggio","year":"2012","journal-title":"J Pediatr"},{"key":"2025091815491414900_ref30","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1097\/INF.0000000000000119","article-title":"Comparative effectiveness of ceftriaxone in combination with a macrolide compared with ceftriaxone alone for pediatric patients hospitalized with community-acquired pneumonia","volume":"33","author":"Leyenaar","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"2025091815491414900_ref31","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1001\/jamapediatrics.2017.3225","article-title":"Effectiveness of \u03b2-lactam monotherapy vs macrolide combination therapy for children hospitalized with pneumonia","volume":"171","author":"Williams","year":"2017","journal-title":"JAMA Pediatr"},{"key":"2025091815491414900_ref32","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1002\/ppul.23312","article-title":"Beta-lactam versus beta-lactam\/macrolide therapy in pediatric outpatient pneumonia","volume":"51","author":"Ambroggio","year":"2016","journal-title":"Pediatr Pulmonol"},{"key":"2025091815491414900_ref33","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1097\/INF.0000000000000740","article-title":"Comparative effectiveness of beta-lactam versus macrolide monotherapy in children with pneumonia diagnosed in the outpatient setting","volume":"34","author":"Ambroggio","year":"2015","journal-title":"Pediatr Infect Dis J"},{"key":"2025091815491414900_ref34","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1097\/00006454-199810000-00004","article-title":"Safety and efficacy of azithromycin in the treatment of community-acquired pneumonia in children","volume":"17","author":"Harris","year":"1998","journal-title":"Pediatr Infect Dis J"},{"key":"2025091815491414900_ref35","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/00006454-199902000-00004","article-title":"Etiology and treatment of community-acquired pneumonia in ambulatory children","volume":"18","author":"Wubbel","year":"1999","journal-title":"Pediatr Infect Dis J"},{"key":"2025091815491414900_ref36","first-page":"704","article-title":"Comparative efficacy of amoxicillin, cefuroxime and clarithromycin in the treatment of community-acquired pneumonia in children","volume":"13","author":"Aurangzeb","year":"2003","journal-title":"J Coll Physicians Surg Pak"},{"key":"2025091815491414900_ref37","volume-title":"Principles and Practice of Pediatric Infectious Diseases","author":"Long","year":"2022","edition":"6th"},{"key":"2025091815491414900_ref38","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1093\/cid\/ciz1059","article-title":"Improved diagnostics help to identify clinical features and biomarkers that predict Mycoplasma pneumoniae community-acquired pneumonia in children","volume":"71","author":"Meyer Sauteur","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2025091815491414900_ref39","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1186\/s13063-024-08438-6","article-title":"A randomized controlled non-inferiority trial of placebo versus macrolide antibiotics for Mycoplasma pneumoniae infection in children with community-acquired pneumonia: trial protocol for the MYTHIC study","volume":"25","author":"Meyer Sauteur","year":"2024","journal-title":"Trials"},{"key":"2025091815491414900_ref40","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1086\/318529","article-title":"Results of molecular detection of Mycoplasma pneumoniae among patients with acute respiratory infection and in their household contacts reveals children as human reservoirs","volume":"183","author":"Dorigo-Zetsma","year":"2001","journal-title":"J Infect Dis"},{"key":"2025091815491414900_ref41","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1093\/jpids\/piy066","article-title":"US emergency department visits for adverse drug events from antibiotics in children, 2011-2015","volume":"8","author":"Lovegrove","year":"2019","journal-title":"J Pediatric Infect Dis Soc"},{"key":"2025091815491414900_ref42","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1093\/jpids\/piaa173","article-title":"Antibiotic-associated adverse events in hospitalized children","volume":"10","author":"Same","year":"2021","journal-title":"J Pediatric Infect Dis Soc"},{"key":"2025091815491414900_ref43","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1007\/s00228-020-02956-3","article-title":"Safety of azithromycin in pediatrics: a systematic review and meta-analysis","volume":"76","author":"Zeng","year":"2020","journal-title":"Eur J Clin Pharmacol"},{"key":"2025091815491414900_ref44","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.ajps.2018.02.001","article-title":"Creation of an assessment system for measuring the bitterness of azithromycin-containing reverse micelles","volume":"13","author":"Huang","year":"2018","journal-title":"Asian J Pharm Sci"},{"key":"2025091815491414900_ref45","doi-asserted-by":"publisher","first-page":"e142","DOI":"10.1016\/S2666-5247(21)00279-2","article-title":"Prevalence of nasopharyngeal Streptococcus pneumoniae carriage and resistance to macrolides in the setting of azithromycin mass drug administration: analysis from a cluster-randomised controlled trial in Malawi, 2015-17","volume":"3","author":"Hart","year":"2022","journal-title":"Lancet Microbe"},{"key":"2025091815491414900_ref46","doi-asserted-by":"publisher","first-page":"00212","DOI":"10.1016\/S1473-3099(25)00212-9","article-title":"Long-term effects of azithromycin mass administration to reduce childhood mortality on Streptococcus pneumoniae antimicrobial resistance: a population-based, cross-sectional, follow-up carriage survey","volume":"S1473-3099","author":"Kalizang'oma","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"2025091815491414900_ref47","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1056\/NEJMoa2002606","article-title":"Macrolide and nonmacrolide resistance with mass azithromycin distribution","volume":"383","author":"Doan","year":"2020","journal-title":"N Engl J Med"},{"key":"2025091815491414900_ref48","doi-asserted-by":"publisher","first-page":"ofy28","DOI":"10.1093\/ofid\/ofy289","article-title":"Effect of commonly used pediatric antibiotics on gut microbial diversity in preschool children in Burkina Faso: a randomized clinical trial","volume":"5","author":"Oldenburg","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"2025091815491414900_ref49","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.ebiom.2018.11.035","article-title":"Short- and long-term impacts of azithromycin treatment on the gut microbiota in children: a double-blind, randomized, placebo-controlled trial","volume":"38","author":"Wei","year":"2018","journal-title":"EBioMedicine"},{"key":"2025091815491414900_ref50","doi-asserted-by":"publisher","first-page":"i17","DOI":"10.1093\/jac\/dkh312","article-title":"Distribution across the USA of macrolide resistance and macrolide resistance mechanisms among Streptococcus pneumoniae isolates collected from patients with respiratory tract infections: PROTEKT US 2001-2002","volume":"54","author":"Farrell","year":"2004","journal-title":"J Antimicrob Chemother"}],"container-title":["Journal of the Pediatric Infectious Diseases Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jpids\/advance-article-pdf\/doi\/10.1093\/jpids\/piaf075\/64044163\/piaf075.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpids\/article-pdf\/14\/9\/piaf075\/64044163\/piaf075.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpids\/article-pdf\/14\/9\/piaf075\/64044163\/piaf075.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T19:49:21Z","timestamp":1758224961000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpids\/article\/doi\/10.1093\/jpids\/piaf075\/8234321"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,14]]},"references-count":50,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9,11]]}},"URL":"https:\/\/doi.org\/10.1093\/jpids\/piaf075","relation":{},"ISSN":["2048-7207"],"issn-type":[{"value":"2048-7207","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,8,14]]},"article-number":"piaf075"}}